Phase II study that evaluated the efficacy and safety of trabedersen (TGF-β2 antisense oligonucleotides) administered intratumorally by convection-enhanced delivery compared with standard chemotherapy in patients with recurrent malignant gliomas showed a superior safety and a trend for superiority in 2-year survival rate of patients with anaplastic astrocytoma compared to chemotherapy [205]. This evidence concerns the gene TGFB2 and malignant glioma.